WHO WE ARE

We are a dual-listed (Euronext Brussels and NASDAQ: TIG) biopharmaceutical company focused on exploiting the anti-inflammatory properties of stem cells to develop novel therapies for serious medical conditions in areas of high unmet medical need.

16 November 2017

TiGenix announces approval of trade name for lead development candidate Cx601 in Europe (ENNLFRES)

6 November 2017

TiGenix announces partial conversion of bonds (EN – NLFRES)

UPCOMING EVENTS

  • INVESTORS AND PARTNERING
  • SCIENTIFIC AND OTHERS

SHARE PRICE

NASDAQ
22.45 USD
Change (%):
0.16 (0.72%)
BRU
0.95 EUR
Change (%):
0.01 (0.63%)